Human Chorionic Gonadotropin (hCG): Physiology, Clinical Uses, Diagnostic Roles, and Safety Considerations

Human chorionic gonadotropin (hCG) is a glycoprotein hormone produced primarily during pregnancy and is central to the diagnosis and management of several reproductive and endocrine conditions. Structurally, hCG is composed of an alpha subunit shared with other pituitary/placental glycoproteins and a beta subunit unique to hCG, conferring specific biological recognition by luteinizing hormone (LH)/hCG receptors. Functionally, hCG acts as a luteotrophic factor: it supports the corpus luteum in early gestation, sustaining progesterone secretion until the placenta can sufficiently produce progesterone and other pregnancy-maintaining signals.

Physiologically, circulating hCG rises after implantation and is detectable in maternal blood and urine. This temporal pattern reflects trophoblastic activity and implantation timing. hCG binds LH/hCG receptors on ovarian luteal cells, leading to increased steroidogenesis and stabilization of the endometrial environment for implantation. Beyond reproduction, hCG can be expressed aberrantly by certain tumors, particularly trophoblastic neoplasms (e.g., choriocarcinoma) and some germ-cell tumors, where it serves both as a biomarker and a driver of endocrine effects.

Clinically, hCG measurement is most widely used for pregnancy testing. Immunoassays detect hCG in urine or serum, typically with high analytical sensitivity for early pregnancy. In serum testing, quantitative hCG provides additional information: the rate of rise can support evaluation of suspected early pregnancy viability. However, single measurements are limited; clinical interpretation must integrate ultrasound findings and patient symptoms.

In reproductive endocrinology, hCG is used therapeutically, especially in assisted reproductive technologies and ovulation induction protocols. Administered hCG can trigger final oocyte maturation and ovulation by mimicking the LH surge. Because the timing and dose influence follicular response, monitoring with serial ultrasound and estradiol measurements is standard to optimize outcomes and reduce risks.

Another major role of hCG is in the evaluation of abnormal uterine bleeding and infertility. For suspected ectopic pregnancy, serial quantitative hCG assessments combined with transvaginal ultrasound help stratify risk and determine whether pregnancy is intrauterine. In general, ectopic and nonviable intrauterine pregnancies may show different hCG trajectories than viable intrauterine pregnancies, though overlap exists. Therefore, clinical algorithms rely on trends and imaging rather than isolated values.

hCG is also a tumor marker. Trophoblastic diseases can produce markedly elevated hCG, enabling diagnosis, monitoring of treatment response, and surveillance for recurrence. Declining hCG after chemotherapy or surgery indicates therapeutic effectiveness, whereas persistent or rising levels suggest residual or recurrent disease. Interpretation must consider assay type and possible “phantom hCG” interference—rare situations where heterophile antibodies or macro-hCG cause misleading results despite the absence of true active hCG production.

Mechanistically, hCG signaling through LH/hCG receptors activates intracellular pathways (e.g., cAMP and steroidogenic gene expression), which supports ovarian function. In males, physiologic hCG is normally absent or minimal; therapeutic use in certain contexts (e.g., fertility preservation in hypogonadotropic hypogonadism) may stimulate Leydig cell testosterone production via LH receptor activity. This can maintain intratesticular testosterone necessary for spermatogenesis when administered alongside or instead of gonadotropins.

Safety considerations depend on the indication and route. For pregnancy testing, hCG is not inherently harmful, but misinterpretation can delay urgent care in ectopic pregnancy or other emergencies. For therapeutic hCG in fertility care, key risks include ovarian hyperstimulation syndrome (OHSS), multiple gestation, and procedure-related complications. Clinicians mitigate OHSS risk through careful stimulation protocols, dose adjustments, and cycle-specific preventive strategies.

Contraindications and cautions vary with patient factors such as known hypersensitivity to gonadotropins, certain ovarian conditions, uncontrolled thyroid or adrenal disease, and specific reproductive tract abnormalities. In tumor settings, treatment decisions must be tailored by staging, metastatic burden, and prior therapy; hCG levels guide ongoing management and long-term surveillance.

For patients, proper understanding of hCG testing limitations is crucial. A positive test generally indicates either pregnancy or hCG production from other sources. False positives can occur due to assay interference or rare medical conditions, while false negatives can occur very early in gestation, with diluted urine, or with technical assay issues. Therefore, confirmatory testing and follow-up intervals are essential when results and symptoms diverge.

In summary, human chorionic gonadotropin is a reproductive and diagnostic cornerstone hormone with roles spanning pregnancy confirmation, evaluation of early pregnancy complications, fertility treatment protocols, and monitoring of trophoblastic and select germ-cell malignancies. Accurate interpretation requires knowledge of assay performance, timing, clinical context, and hCG kinetics.

Source: [@sgencel2001] (Human Chorionic Gonadotropin post)